Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Nurix Therapeutics, Inc.’s reported figures.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026. Open the filing →
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
FAQ
- What is Nurix Therapeutics, Inc.'s EBITDA?
- Nurix Therapeutics, Inc. (NRIX) reported EBITDA of -$91.95M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s EBITDA changed year-over-year?
- Nurix Therapeutics, Inc.'s EBITDA decreased by 99.5% year-over-year, from -$46.08M to -$91.95M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s EBITDA has grown at a 24.5% compound annual growth rate (CAGR), from -$115.19M to -$276.93M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Nurix Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude